Form D · Biotechnology
Crossbow Therapeutics, Inc.
Cambridge, MA · CIK 0001972912
Offering snapshot reported Sep 30, 2025 · SEC filing
- Reported sold
- $30.3M Offering amount: $80M
- Investors reported
- 17 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 17, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 30, 2025 | Initial | $30,250,000 | No comparison | 17 | SEC filing |
| Apr 12, 2023 | Initial | $37,568,164 | No comparison | 15 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-559257
Source: Form D, filed Sep 30, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Sakae Asanuma | Director |
| Charles Baum | Director |
| Alexandra Cantley | Director |
| Todd Foley | Director |
| Alon Lazarus | Director |
| Irena Melnikova | Director |
| Briggs Morrison | Director, Executive, Promoter |
| Alexander Nolte | Executive |
| Geraldine Paulus | Executive |
| Dmitri Wiederschain | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1030 Massachusetts Ave, Suite 210
Cambridge, MA, 02138
Cambridge, MA, 02138